Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this ...

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data indicate ...

The speed of medicine has changed. Healthcare professionals are no longer waiting for conferences or clinical guidelines to make key decisions. In fast-paced clinical settings, physicians are actively ...